Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Supports analytical and clinical validation of cancer-related molecular, cellular, and imaging biomarkers and assays on human samples for a clearly defined intended use.
⚑ Clinical trial not allowed despite UH2/UH3 phrasing. · Foreign organizations and non-domestic components of U.S. organizations are not eligible; foreign components are allowed. · Applicants should check Section III for any additional NIH eligibility limits.
This is a biomedical assay-validation cancer program, centered on human samples, molecular markers, and clinical oncology—well outside IPPRA’s social-behavioral/public opinion and policy research lines. The team would not plausibly pursue this as PI-level work, beyond perhaps tangential interest in communication or policy implications.
JUDGED AGAINST THE ROSTER'S PUBLICATION DOSSIER · GPT-5.4-MINI · 2026-11-04
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 55 good | technical depth: minor; funds applied research |
| IPPRA | 45 partial | peripheral portfolio topic: public_health; social/behavioral work is none; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped); capped at 45 (limited social-science role) |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Apply
View on Grants.gov → CONTACT: National Institutes of Health <NCICDPNOFO@mail.nih.gov>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →
Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.